» Articles » PMID: 16461184

Role of Aldosterone in Left Ventricular Hypertrophy in Hypertension

Overview
Journal Am J Hypertens
Date 2006 Feb 8
PMID 16461184
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Aldosterone induces cardiac fibrosis in experimental animal models, but only limited information is available on the association between aldosterone and left ventricular (LV) hypertrophy in human beings. The aim of the present study was to determine the role of aldosterone in LV geometry and to investigate other types of target organ damage in hypertensive patients.

Methods: A total of 25 patients with primary aldosteronism caused by Conn's adenoma, 29 patients with renovascular hypertension, and 29 patients with essential hypertension (EHT) were included in the present study. Echocardiographic examinations and 24-h ambulatory blood pressure (BP) monitoring were conducted in all subjects.

Results: The mean 24-h systolic and diastolic BP in primary aldosteronism and renovascular hypertension were found to be comparable to those in EHT. However, LV mass index adjusted by age, sex, mean 24-h systolic BP, mean 24-h pulse rate, body mass index, and duration of hypertension was significantly increased in the patients with primary aldosteronism and renovascular hypertension compared with values in patients with EHT (150.2 +/- 7.7, 142.3 +/- 7.2, and 115.2 +/- 7.2 g/m(2), respectively). Hypertensive organ damages, such as proteinuria and hypertensive retinopathy, were more pronounced in the patients with renovascular hypertension; however, LV hypertrophy was especially exaggerated in patients with primary aldosteronism.

Conclusions: These results indicate that aldosterone may induce LV hypertrophy in human beings as well as in experimental animals, and that angiotensin II and aldosterone may differentially participate in causing hypertensive target organ damage.

Citing Articles

Evaluating the effects of adrenalectomy and mineralocorticoid receptor antagonist on cardiac remodeling and diastolic function in patients with aldosterone-producing adenoma.

Chang Y, Wu X, Chen T, Chen U, Liao C, Lai T Hypertens Res. 2024; 48(2):529-539.

PMID: 39448809 DOI: 10.1038/s41440-024-01946-7.


Recent progress in unraveling cardiovascular complications associated with primary aldosteronism: a succinct review.

Wang W, Wu T, Er L, Huang C, Tu K, Fan K Hypertens Res. 2024; 47(5):1103-1119.

PMID: 38228750 DOI: 10.1038/s41440-023-01538-x.


The Effect of Aldosterone on Cardiorenal and Metabolic Systems.

Otsuka H, Abe M, Kobayashi H Int J Mol Sci. 2023; 24(6).

PMID: 36982445 PMC: 10049192. DOI: 10.3390/ijms24065370.


Cardiovascular and metabolic characters of somatic mutations in primary aldosteronism.

Chang Y, Lee B, Chen Z, Tsai C, Chang C, Liao C Front Endocrinol (Lausanne). 2023; 14:1061704.

PMID: 36950676 PMC: 10025475. DOI: 10.3389/fendo.2023.1061704.


Spironolactone as a Potential New Treatment to Prevent Arrhythmias in Arrhythmogenic Cardiomyopathy Cell Model.

Reisqs J, Moreau A, Sleiman Y, Charrabi A, Deliniere A, Bessiere F J Pers Med. 2023; 13(2).

PMID: 36836569 PMC: 9960914. DOI: 10.3390/jpm13020335.